1600025M17Rik Activators
1600025M17Rik Activators represent a spectrum of chemical compounds that indirectly enhance the activity of the protein product of the 1600025M17Rik gene. Forskolin, Isoproterenol, and Dibutyryl-cAMP all function to increase intracellular cAMP levels, which in turn activates PKA, leading to the phosphorylation of proteins that may interact with 1600025M17Rik, potentially enhancing its functional activity. Phorbol 12-myristate 13-acetate (PMA) and Ionomycin work through PKC and calcium-dependent pathways, respectively. PMA's activation of PKC could result in the phosphorylation of substrates that interact with 1600025M17Rik, while Ionomycin's elevation of intracellular calcium levels may activate calcium-dependent proteins and pathways that indirectly augment 1600025M17Rik activity. Furthermore, IBMX, by inhibiting phosphodiesterases, sustains cAMP levels, thereby indirectly promoting 1600025M17Rik's function via PKA.
Continuing the exploration of activators, Epigallocatechin gallate (EGCG) and LY294002, through their inhibition of tyrosine kinases and PI3K respectively, may relieve competitive inhibition of pathways involving 1600025M17Rik, thereby enhancing its activity. Similarly, PD 98059 and SB203580, by inhibiting MEK and p38 MAPK, could shift signaling dynamics in favor of 1600025M17Rik activation. Anisomycin, aside from inhibiting protein synthesis, may activate stress-activated protein kinases that indirectly support the functional activity of 1600025M17Rik. Lastly, Spermidine, by modulating intracellular signaling, provides a conducive environment for the enhanced activity of the 1600025M17Rik protein by influencing signaling pathways and cellular homeostasis. Collectively, these compounds comprise a putative network of indirect activators that enrich the functional landscape of the 1600025M17Rik protein without directly increasing its expression levels or engaging in direct activation mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate substrates that could interact with 1600025M17Rik, thus potentially enhancing its activity through downstream signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium-dependent proteins and pathways that may indirectly enhance the activity of the 1600025M17Rik protein. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels, potentially enhancing the activity of 1600025M17Rik by activating PKA and phosphorylating interaction partners of the protein. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents cAMP degradation, potentially increasing the activity of PKA and enhancing the functional activity of the 1600025M17Rik protein. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
db-cAMP is a cAMP analog that activates PKA. PKA phosphorylation of substrates could indirectly enhance the activity of the 1600025M17Rik protein by modulating interacting signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that may decrease competitive signaling pathways, potentially allowing for the activation or enhancement of pathways involving the 1600025M17Rik protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that may shift signaling dynamics, possibly enhancing pathways that indirectly activate the 1600025M17Rik protein by reducing competitive signaling through the AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that could potentially alter the activity of ERK, which may interact with or affect signaling pathways related to the 1600025M17Rik protein, thus enhancing its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that may shift signaling to favor pathways involving the 1600025M17Rik protein, potentially enhancing its activity by reducing competition from p38 MAPK signaling. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can also activate stress-activated protein kinases, potentially influencing pathways that enhance the activity of the 1600025M17Rik protein indirectly. | ||||||